Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial.
Gullestad
Lars
L
Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. lars.gullestad@medisin.uio.no
Mortensen
Svend-Aage
SA
Eiskjær
Hans
H
Riise
Gerdt C
GC
Mared
Lena
L
Bjørtuft
Oystein
O
Ekmehag
Björn
B
Jansson
Kjell
K
Simonsen
Svein
S
Gude
Einar
E
Rundqvist
Bengt
B
Fagertun
Hans E
HE
Solbu
Dag
D
Iversen
Martin
M
D048868:Adaptor Proteins, Signal Transducing / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D000068338:Everolimus; D005919:Glomerular Filtration Rate; D006084:Graft Rejection / Q000453:epidemiology; D016027:Heart Transplantation / Q000276:immunology / Q000502:physiology*; D016041:Heart-Lung Transplantation / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D016040:Lung Transplantation / Q000276:immunology / Q000502:physiology*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
D048868:Adaptor Proteins, Signal Transducing; C491861:CABIN1 protein, human; D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus